Capital Performance


In this report, Criticaleye's Growth Company Retreat Partner, finnCap, discusses the performance of the markets in the challenging year that 2021 proved to be and predicts some future trends and patterns for 2022.

Key takeaways include:

  • Capital markets remain supportive for high-growth companies. However, structure and timing will be key for continued success, particularly when competition is fierce.
  • Future 2022 UK M&A trends include Private Equity activity, ESG, due diligence environments and the technology sector.
  • In the first three quarters of 2021, global M&A activity increased by 47 percent of deals made, equalling nearly $4.3 trillion compared to the same period in 2020.

Share this with your Community




Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Inspiring Leaders Podcast: Wh...

Matthew Blagg, CEO for Criticaleye, joins Marketing and Communications Director Julia Brook for the first Inspiring Leaders podcast for 2026. They take a look at some of the lessons for leaders last year, and examin...

Inspiring Leaders Podcast: Na...

Dave Wilson, Chair of LBG Media (LADbible) and Knights plc, joins Criticaleye’s Senior Editor Jacob Ambrose Willson to explore how Boards and executive teams can successfully navigate today’s capital markets...

Click here to download this insight
2026 Enterprise Software Tech...

In this report, Criticaleye Partner AlixPartners suggest that 2026 will likely mark a structural turning point for enterprise software, as AI reshapes not only how software is built, but how it is priced,...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 436




Drax Group plc IBM Consulting E.ON UK FTSE Women Leaders Review Accenture Google AlixPartners Legal & General Workday Hitachi Solutions Aldermore Group British Land Concentrix NATS London Stock Exchange Group Palo Alto Networks Worldpay Salesforce Rolls-Royce NatWest Group Lightsource bp Eightfold AI GlaxoSmithKline plc